INSMInsmed Incorporated
$100.66-30% 1Y
$100.66
$91.8852 weeks$211.41
The financials
Insmed Incorporated by the numbers
Insmed Incorporated (INSM) reported revenue of $425M in Q2 2026 (quarter ended Jun 30, 2026), up 296% from the same quarter a year earlier. That came with a gross margin of 84% and net loss of $13M. For the full year FY2025, revenue was $606M (+67% year on year) and net income −$1.28B. Its largest region in Q2 2026 was United States at $70M, 60% of the disclosed total, well ahead of Non Us at 40%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $425M | $107M | +296% |
| Gross profit | $358M | $79M | +352% |
| Operating income | −$1.5M | −$313M | n/a |
| Net income | −$13M | −$322M | n/a |
| Diluted EPS | −$0.06 | −$1.70 | n/a |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $70M | 60% |
| Non Us | $46M | 40% |
Business segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q2 2026Total $116.3M (+19%)
Non Us grew +19% year on yearUnited States +2.2% year on year
Segment Latestquarter on quarteryear on year
- United States$70.2M$70.2Mquarter on quarter +12%year on year +2.2%+12%+2.2%
- Non Us$46.1M$46.1Mquarter on quarter +31%year on year +19%+31%+19%
Biotechnology
Ranks #38 of 196 by RyuScore